Industry

ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficacy levels comparable to intravenous (IV) docetaxel Based on strong safety data and encouraging efficacy from the randomized Phase 2b trial, the 20-20/200-100mg dose has been selected for use in planned Phase 3 clinical trial AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (“Modra”) today announced the final … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Healthcare Interoperability Solutions Market Research Report by Component (Services and Software), Level, End-User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Healthcare Interoperability Solutions Market size was estimated at USD 2,934.37 million in … [Read more…]

Water Bottle Caps with Integrated Deep UV LEDs Recognized for Excellence in Business to Consumer: Travel, Sports & Outdoor Goods BERLIN–(BUSINESS WIRE)–#sustainablehydration–During an awards ceremony on May 24, 2022, the German Innovation Awards named both WAATR PureMax 4D and CrazyCap as winners in Business to Consumer: Travel, Sports & Outdoor Goods. The German Innovation Award … [Read more…]

13 of 16 metastatic Uveal Melanoma (UM) patients continue in trial with promising overall survival rate at 1 year Excellent safety allowed for chronic administration with no dose alterations, achieving intended pharmacological effect Tregs reduced by IOA-244 in peripheral blood and tumor tissue, supporting mechanism of action GENEVA, Switzerland–(BUSINESS WIRE)–iOnctura SA, a clinical-stage oncology company … [Read more…]

STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical … [Read more…]

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021   The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. … [Read more…]

– ALPN-303 Novel Preclinical Data and Preliminary Phase 1 Data at EULAR – – Davoceticept (ALPN-202) Monotherapy Update and Trials in Progress Poster for Pembrolizumab Combination Study at ASCO – SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today … [Read more…]

– Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months – Study sites are open for patient enrolment LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today … [Read more…]

NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7. “As demonstrated by our research at ASCO this year, we are at the forefront of our industry to improve patient lives through … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combination with immune checkpoint inhibitors. AU-011 is being developed for the treatment of life-threatening cancers … [Read more…]